MedPath

Effect of Mucolytic in treatment of cystic fibrosis

Phase 2
Conditions
Cystic fibrosis.
Cystic fibrosis with pulmonary manifestations
Registration Number
IRCT20180307038994N1
Lead Sponsor
Shahid Beheshti University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
30
Inclusion Criteria

Patients with cystic fibrosis older than 5 years
Ability to perform spirometery

Exclusion Criteria

Age less than 5 years

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Pulmonary function based on spirometry. Timepoint: Spirometry at the beginning of study and at the end of study after two weeks of treatment. Method of measurement: Spirometry device.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath